Rosenblum Silverman Sutton S F Has Decreased Fidelity National Information Services I (FIS) Stake By $439,815; Therapix Biosciences LTD. – American Depositary SH (TRPX) Shorts Decreased By 16.71%

Fidelity National Information Services, Inc. (NYSE:FIS) Logo

Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX) had a decrease of 16.71% in short interest. TRPX’s SI was 175,900 shares in February as released by FINRA. Its down 16.71% from 211,200 shares previously. With 224,300 avg volume, 1 days are for Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX)’s short sellers to cover TRPX’s short positions. The SI to Therapix Biosciences LTD. – American Depositary SH’s float is 5.88%. The stock increased 3.45% or $0.1386 during the last trading session, reaching $4.1586. About 20,673 shares traded. Therapix Biosciences Ltd. (NASDAQ:TRPX) has risen 2.08% since February 13, 2018 and is uptrending. It has outperformed by 2.08% the S&P500.

Rosenblum Silverman Sutton S F Inc decreased Fidelity National Information Services I (FIS) stake by 5.78% reported in 2018Q3 SEC filing. Rosenblum Silverman Sutton S F Inc sold 4,035 shares as Fidelity National Information Services I (FIS)’s stock declined 2.80%. The Rosenblum Silverman Sutton S F Inc holds 65,721 shares with $7.17 million value, down from 69,756 last quarter. Fidelity National Information Services I now has $35.05 billion valuation. The stock increased 0.45% or $0.48 during the last trading session, reaching $107.03. About 1.31M shares traded. Fidelity National Information Services, Inc. (NYSE:FIS) has risen 10.23% since February 13, 2018 and is uptrending. It has outperformed by 10.23% the S&P500. Some Historical FIS News: 31/05/2018 – New Research Coverage Highlights Constellation Brands, Yintech Investment, EZCORP, Euronet Worldwide, Fidelity National Financi; 09/04/2018 – Fidelity National Information: Norcross Is Also President, CEO; 01/05/2018 – FIDELITY NATIONAL SEES FY REV. -1.5% TO -2.5%; 01/05/2018 – Fidelity National Raises 2018 View To EPS $3.04-EPS $3.39; 08/05/2018 – FIDELITY NATIONAL INFORMATION SERVICES INC – SEES 2021 PROJECTED EPS OF $7.00 TO $ 7.50; 01/05/2018 – Fidelity National: Raises full-Yr EPS Guidance; 11/04/2018 – FIS Recognizes Ten Clients for Innovation in 2018 Impact Awards; 14/05/2018 – S&PGR Rts Fidelity National Info Services’ Sr Unsecd Nts ‘BBB’; 08/05/2018 – FIDELITY NATIONAL TARGETS 2021 EPS OF $7-$7.50: SLIDES; 22/03/2018 – Fidelity National Closes Below 50-Day Moving Average

More notable recent Therapix Biosciences Ltd. (NASDAQ:TRPX) news were published by: Seekingalpha.com which released: “Therapix Bio up 26% – Seeking Alpha” on February 04, 2019, also Seekingalpha.com with their article: “Microcaps dominate midday movers – Seeking Alpha” published on February 04, 2019, Benzinga.com published: “56 Biggest Movers From Yesterday – Benzinga” on February 05, 2019. More interesting news about Therapix Biosciences Ltd. (NASDAQ:TRPX) were released by: Benzinga.com and their article: “34 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” published on January 17, 2019 as well as Seekingalpha.com‘s news article titled: “Evolus leads healthcare gainers; Fortress Biotech and Check-Cap among losers – Seeking Alpha” with publication date: February 04, 2019.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company has market cap of $14.54 million. The Company’s drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome ; and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. It currently has negative earnings. The firm was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013.

Among 4 analysts covering Fidelity National Info (NYSE:FIS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fidelity National Info had 4 analyst reports since October 31, 2018 according to SRatingsIntel. Goldman Sachs upgraded the stock to “Buy” rating in Tuesday, December 11 report. The stock of Fidelity National Information Services, Inc. (NYSE:FIS) has “Buy” rating given on Wednesday, October 31 by Citigroup. Cantor Fitzgerald maintained it with “Overweight” rating and $122 target in Wednesday, October 31 report.

Investors sentiment increased to 1.07 in Q3 2018. Its up 0.13, from 0.94 in 2018Q2. It is positive, as 22 investors sold FIS shares while 206 reduced holdings. 69 funds opened positions while 176 raised stakes. 279.20 million shares or 0.68% less from 281.11 million shares in 2018Q2 were reported. Moreover, State Street has 0.11% invested in Fidelity National Information Services, Inc. (NYSE:FIS). New York-based Mufg Americas Hldgs Corporation has invested 0% in Fidelity National Information Services, Inc. (NYSE:FIS). Channing Cap Limited Liability Company holds 0.35% or 89,990 shares in its portfolio. San Francisco Sentry Inv Group (Ca) has 157 shares. Blackrock Inc holds 26.06M shares or 0.12% of its portfolio. Btc Cap Mngmt holds 0.13% or 6,929 shares in its portfolio. 26,630 were accumulated by Pennsylvania. Ontario Teachers Pension Plan Board holds 0.03% or 18,377 shares in its portfolio. 839,808 were accumulated by Lord Abbett & Communications Ltd Liability. Salem Inv Counselors has 0.01% invested in Fidelity National Information Services, Inc. (NYSE:FIS). Ls Invest Advsr Ltd Liability reported 0.14% in Fidelity National Information Services, Inc. (NYSE:FIS). Gabelli Funds Ltd invested 0.08% in Fidelity National Information Services, Inc. (NYSE:FIS). North Star Inv Management reported 1,117 shares stake. Advisor reported 7,920 shares stake. World Asset Mgmt Inc has invested 0.1% in Fidelity National Information Services, Inc. (NYSE:FIS).

Fidelity National Information Services, Inc. (NYSE:FIS) Institutional Positions Chart